Idexx Laboratories AI Stock Analysis
Want to see IDXX full AI Analyst Report?
Idexx Laboratories (IDXX) AI Stock Analysis
Idexx Laboratories
(NASDAQ:IDXX)
IDXX scores well overall on high-quality financial performance (strong margins, cash flow, and improving leverage) and a constructive earnings update with raised guidance. The score is tempered by stretched technical conditions (overbought signals) and a high valuation (P/E ~45), which increase downside sensitivity if growth or margins disappoint.
Idexx Laboratories Key Performance Indicators (KPIs)
Revenue by GeographyBreaks revenue down by region (U.S., Europe, Rest of World), showing where Idexx earns most sales and which markets are growing fastest. Helps investors assess dependence on mature versus emerging markets, local veterinary demand trends, and exposure to currency and regional economic risk.
International revenue has moved from steady growth to pronounced acceleration beginning mid‑2025, driven by stronger recurring diagnostics overseas and faster adoption of premium instruments and tests (inVue Dx, Cancer Dx, Water/LPD momentum). That international strength underpins the upgraded guidance, margin expansion and robust cash generation, and helps offset U.S. clinic/visit softness; risks to watch are foreign‑exchange headwinds and the prior‑year instrument revenue lap — durable consumable attach and continued placements will determine sustainability.
Idexx Laboratories (IDXX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $55.20B
- Dividend Yield
- ―
- Average Volume (3M)
- 562.62K
- Price to Earnings (P/E)
- 47.4
- Beta (1Y)
- 0.62
- Revenue Growth
- 11.87%
- EPS Growth
- 17.33%
- Country
- US
- Employees
- 11,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Idexx Laboratories Business Overview & Revenue Model
Company Description
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dair...
How the Company Makes Money
IDEXX makes money primarily by selling veterinary diagnostic products and delivering recurring diagnostic services, supported by long-term customer relationships with veterinary practices and laboratories. Its major revenue streams include: (1) Compa...
Idexx Laboratories Earnings Call Summary
The call was strongly positive overall. IDEXX reported broad-based organic growth, double-digit gains in key recurring-revenue businesses, expanding international execution, strong instrument and innovation adoption, improved margins, higher EPS, and raised full-year guidance. The main challenges were declining U.S. clinical visits, muted puppy and kitten adoption, modest rapid assay growth, foreign exchange pressure, and near-term ezyVet-related dilution and costs.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, IDEXX raised its revenue outlook to $4.741 billion to $4.767 billion, a $32 million increase at midpoint, with reported revenue growth of 10.1% to 10.8%, overall organic revenue growth of 9.3% to 10%, and organic CAG Diagnostics recurring revenue growth of 10.3% to 11%, including approximately 4% benefit from global net price realization; the ranges represent an increase of approximately 60 basis points at midpoint along with tightening the low end of the range. EPS guidance increased to $14.96 to $15.16 per share, a $0.25 per share increase at midpoint, reflecting 15% to 16% comparable EPS growth, a tax rate estimated at 20.5%, lower net interest expense of approximately $32 million, approximately $0.13 per share of dilution related to ezyVet, $0.25 per share of foreign exchange benefits, $19 million or $0.24 per share of share-based compensation benefits, and a 2% reduction in average diluted shares outstanding. Reported operating margin guidance is 32.1% to 32.3%, reflecting 50 to 70 basis points of full year comparable operating margin improvement and approximately 30 basis points of negative impact related to ezyVet; free cash flow conversion is expected to be 95% to 100% of net income, with capital spending of approximately $160 million. For the fourth quarter, reported operating margins are expected to be 28.4% to 29.3%, with an approximately 70-basis-point headwind from foreign currency partially offset by benefits from the ezyVet acquisition; a 1% strengthening of the US dollar would reduce revenue by approximately $4 million and EPS by $0.02 per share for the remainder of the year.
Idexx Laboratories Financial Statement Overview
Summary
Strong profitability and cash generation: ~62.7% TTM gross margin and ~25.4% TTM net margin with improving operating leverage, plus robust free cash flow (~$1.30B) and healthy conversion (~92% of net income). Balance sheet leverage has improved (debt/equity down to ~0.52x TTM), though still a watch item. A key caution is sustainability/comparability of the unusually outsized TTM growth cited versus the steadier historical trend.
Income Statement
91Very PositiveBalance Sheet
78PositiveCash Flow
88Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.66B | 4.30B | 3.90B | 3.66B | 3.37B | 3.22B |
| Gross Profit | 2.92B | 2.66B | 2.38B | 2.19B | 2.00B | 1.89B |
| EBITDA | 1.67B | 1.51B | 1.28B | 1.22B | 1.01B | 1.04B |
| Net Income | 1.18B | 1.06B | 887.87M | 845.04M | 679.09M | 744.85M |
Balance Sheet | ||||||
| Total Assets | 3.71B | 3.35B | 3.29B | 3.26B | 2.75B | 2.44B |
| Cash, Cash Equivalents and Short-Term Investments | 197.54M | 180.07M | 288.27M | 453.93M | 112.55M | 144.45M |
| Total Debt | 972.96M | 1.08B | 986.95M | 1.07B | 1.47B | 1.03B |
| Total Liabilities | 1.84B | 1.75B | 1.70B | 1.78B | 2.14B | 1.75B |
| Stockholders Equity | 1.87B | 1.61B | 1.60B | 1.48B | 608.74M | 689.99M |
Cash Flow | ||||||
| Free Cash Flow | 1.30B | 1.06B | 798.08M | 772.88M | 394.15M | 636.00M |
| Operating Cash Flow | 1.42B | 1.18B | 929.00M | 906.51M | 542.98M | 755.55M |
| Investing Cash Flow | -335.27M | -136.24M | -207.06M | -125.25M | -195.35M | -292.97M |
| Financing Cash Flow | -1.09B | -1.16B | -878.07M | -442.00M | -370.94M | -697.41M |
Idexx Laboratories Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXX, the sentiment is Positive. The current price of 700.65 is above the 20-day moving average (MA) of 632.89, above the 50-day MA of 565.71, and above the 200-day MA of 572.50, indicating a bullish trend. The MACD of 43.31 indicates Negative momentum. The RSI at 70.23 is Negative, neither overbought nor oversold. The STOCH value of 82.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDXX.
Idexx Laboratories Risk Analysis
Idexx Laboratories disclosed 24 risk factors in its most recent earnings report. Idexx Laboratories reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
1 New RiskIdexx Laboratories Peers Comparison
Overall Rating
IDXX82Outperform
TMO76.9Outperform
A75Outperform
ILMN75Outperform
DHR73Outperform
WAT59Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | $55.20B | 47.37 | 71.18% | ― | 11.87% | 17.33% | |
| 77Outperform | $256.15B | 36.40 | 13.31% | 0.27% | 8.27% | 9.59% | |
| 75Outperform | $48.75B | 34.01 | 20.47% | 0.59% | 8.60% | 19.07% | |
| 75Outperform | $29.94B | 33.88 | 31.45% | ― | 6.00% | 31.48% | |
| 73Outperform | $161.75B | 37.78 | 8.18% | 0.66% | 5.52% | 25.53% | |
| 59Neutral | $44.56B | 192.94 | 0.81% | ― | 80.68% | -78.49% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IDXX | Idexx Laboratories | 700.65 | 3.55 | 0.51% | |
| A | Agilent Technologies | 172.92 | 29.60 | 20.65% | |
| DHR | Danaher Corporation | 229.91 | 9.13 | 4.14% | |
| ILMN | Illumina | 198.00 | 77.88 | 64.84% | |
| TMO | Thermo Fisher Scientific | 691.33 | 119.55 | 20.91% | |
| WAT | Waters Corp | 453.42 | 77.17 | 20.51% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
